Unknown

Dataset Information

0

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.


ABSTRACT: CD34+ cell selection significantly improves GvHD-free survival in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, specific information regarding long-term prognosis and risk factors for late mortality after CD34+ cell-selected allo-HSCT is lacking. We conducted a single-center landmark analysis in 276 patients alive without relapse 1 year after CD34+ cell-selected allo-HSCT for AML (n=164), ALL (n=33) or myelodysplastic syndrome (n=79). At 5 years' follow-up after the 1-year landmark (range 0.03-13 years), estimated relapse-free survival (RFS) was 73% and overall survival (OS) 76%. The 5-year cumulative incidence of relapse and non-relapse mortality (NRM) were 11% and 16%, respectively. In multivariate analysis, Hematopoietic Cell Transplantation Comorbidity Index score?3 correlated with marginally worse RFS (hazard ratio (HR) 1.78, 95% confidence interval (CI) 0.97-3.28, P=0.06) and significantly worse OS (HR 2.53, 95% CI 1.26-5.08, P=0.004). Despite only 24% of patients with acute GvHD within 1 year, this also significantly correlated with worse RFS and OS, with increasing grades of acute GvHD associating with increasingly poorer survival on multivariate analysis (P<0.0001). Of 63 deaths after the landmark, GvHD accounted for 27% of deaths and was the most common cause of late mortality, followed by relapse and infection. Although prognosis is excellent for patients alive without relapse 1 year after CD34+ cell-selected allo-HSCT, risks of late relapse and NRM persist, particularly due to GvHD.

SUBMITTER: Cho C 

PROVIDER: S-EPMC5718946 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Cho C C   Hsu M M   Barba P P   Maloy M A MA   Avecilla S T ST   Barker J N JN   Castro-Malaspina H H   Giralt S A SA   Jakubowski A A AA   Koehne G G   Meagher R C RC   O'Reilly R J RJ   Papadopoulos E B EB   Ponce D M DM   Tamari R R   van den Brink M R M MRM   Young J W JW   Devlin S M SM   Perales M-A MA  

Bone marrow transplantation 20171009 12


CD34+ cell selection significantly improves GvHD-free survival in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, specific information regarding long-term prognosis and risk factors for late mortality after CD34+ cell-selected allo-HSCT is lacking. We conducted a single-center landmark analysis in 276 patients alive without relapse 1 year after CD34+ cell-selected allo-HSCT for AML (n=164), ALL (n=33) or myelodysplastic syndrome (n=79). At 5 years' follow-up after the 1-  ...[more]

Similar Datasets

| S-EPMC4975432 | biostudies-literature
| S-EPMC4949094 | biostudies-literature
| S-EPMC6731766 | biostudies-literature
| S-EPMC8945304 | biostudies-literature
| S-EPMC5182101 | biostudies-literature
| S-EPMC7302932 | biostudies-literature
| S-EPMC7609585 | biostudies-literature
| S-EPMC6142540 | biostudies-literature
| S-EPMC10027501 | biostudies-literature
| S-EPMC7973115 | biostudies-literature